<div id="readability-page-1"><p>Norges Bank acquired a new stake in shares of  CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 406,487 shares of the company's stock, valued at approximately $19,772,000. Norges Bank owned approximately 0.45% of CRISPR Therapeutics at the end of the most recent reporting period.</p><div><p><span></span><span>Get <strong>CRISPR Therapeutics</strong> alerts:</span></p></div><ul><li>CRSPR Stock Could Be Ready to Deliver on Its Massive Promise</li></ul><p>Several other institutional investors and hedge funds also recently added to or reduced their stakes in CRSP. IVC Wealth Advisors LLC bought a new stake in shares of  CRISPR Therapeutics in the 2nd quarter valued at about $225,000.  Koss Olinger Consulting LLC raised its stake in shares of  CRISPR Therapeutics by 29.8% during the 2nd quarter. Koss Olinger Consulting LLC now owns 42,197 shares of the company's stock worth $2,052,000 after acquiring an additional 9,685 shares in the last quarter.  Vanguard Group Inc. lifted its position in  CRISPR Therapeutics by 1.9% during the first quarter. Vanguard Group Inc. now owns 1,769,709 shares of the company's stock valued at $60,223,000 after acquiring an additional 33,711 shares during the last quarter.  Slow Capital Inc. boosted its stake in  CRISPR Therapeutics by 15.6% in the second quarter. Slow Capital Inc. now owns 75,396 shares of the company's stock valued at $3,667,000 after acquiring an additional 10,152 shares in the last quarter.  Finally, Legal &amp; General Group Plc boosted its stake in  CRISPR Therapeutics by 59.7% in the second quarter. Legal &amp; General Group Plc now owns 129,567 shares of the company's stock valued at $6,302,000 after acquiring an additional 48,412 shares in the last quarter. Hedge funds and other institutional investors own  69.20% of the company's stock. </p><h2>Analysts Set New Price Targets</h2><p>Several analysts have recently commented on the company. Wedbush decreased their price objective on CRISPR Therapeutics from $13.00 to $9.00 and set an &#34;outperform&#34; rating for the company in a report on Wednesday, November 5th. Wells Fargo &amp; Company  set a $75.00 price target on CRISPR Therapeutics in a research note on Monday, October 13th. Citigroup  reissued a &#34;buy&#34; rating and issued a $77.00 price target (down previously from $87.00) on shares of CRISPR Therapeutics in a report on Tuesday, November 11th. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of CRISPR Therapeutics in a research note on Wednesday, October 8th. Finally, Robert W. Baird decreased their price objective on shares of CRISPR Therapeutics from $52.00 to $44.00 and set a &#34;neutral&#34; rating for the company in a research report on Tuesday, November 11th. Eleven investment analysts have rated the stock with a Buy rating, eight have assigned  a Hold rating and two have assigned  a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of &#34;Hold&#34; and a consensus target price of $67.42.</p><ul><li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li></ul><p><b>Get Our Latest Report on CRISPR Therapeutics</b></p><h2>CRISPR Therapeutics Price Performance</h2><p>NASDAQ CRSP opened at $57.36 on Tuesday. CRISPR Therapeutics AG has a 1 year low of $30.04 and a 1 year high of $78.48. The company has a market capitalization of $5.47 billion, a PE ratio of -10.26 and a beta of 1.74. The company has a fifty day moving average of $61.17 and a 200 day moving average of $55.61. </p><ul><li>2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025</li></ul><p>CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings data on Monday, November 10th. The company reported ($1.17) earnings per share for the quarter, beating analysts' consensus estimates of ($1.32) by $0.15. The business had revenue of $0.89 million during the quarter, compared to analyst estimates of $8.74 million. CRISPR Therapeutics had a negative return on equity of 21.23% and a negative net margin of 1,273.70%. Research analysts expect that  CRISPR Therapeutics AG will post -5.16 earnings per share for the current year. </p><h2>Insider Activity at CRISPR Therapeutics</h2><p>In other news, CEO Samarth Kulkarni sold 50,895 shares of the firm's stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $67.91, for a total transaction of $3,456,279.45. Following the sale, the chief executive officer owned 254,201 shares of the company's stock, valued at $17,262,789.91. This trade represents a 16.68% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, General Counsel James R. Kasinger sold 1,076 shares of CRISPR Therapeutics stock in a transaction that occurred on Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total transaction of $71,661.60. Following the transaction, the general counsel directly owned 83,402 shares of the company's stock, valued at approximately $5,554,573.20. This trade represents a 1.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 56,213 shares of company stock valued at $3,810,458. 4.10% of the stock is owned by company insiders. </p><h2>CRISPR Therapeutics Company Profile</h2> (Free Report)<p>CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than CRISPR Therapeutics</li><li>What is the Shanghai Stock Exchange Composite Index?</li><li>What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health</li><li>What Are Dividend Challengers?</li><li>3 Stocks Most Likely to Split in 2026</li><li>Pets Are Big Business: 4 Big-Ticket Pet Stocks to Add to Your Portfolio</li><li>ChargePoint's Comeback Story: Why This EV Stock Is Charging Up Again</li></ul><p><strong>Want to see what other hedge funds are holding CRSP?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in CRISPR Therapeutics Right Now?</h2><p>Before you consider CRISPR Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.</p><p>While CRISPR Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CRSP

<p>Norges Bank acquired a new stake in CRISPR Therapeutics AG, purchasing 406,487 shares valued at $19.77 million during the second quarter. This investment represents 0.45% ownership of CRISPR Therapeutics. Other institutional investors also adjusted their stakes in the company. Analysts have varied ratings on CRISPR Therapeutics, with a consensus target price of $67.42. The company reported quarterly earnings, beating estimates, but with negative margins. CEO Samarth Kulkarni sold shares, reducing his position by 16.68%.</p>

Norges Bank Invests $19.77 Million in CRISPR Therapeutics AG $CRSP